Type 2 Diabetes

The OPTIFAST meal replacement program resulted in better outcomes than the standard of care and a higher proportion of patients no longer meeting criteria for type 2 diabetes.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Despite several of these 2 medicines have proved to reduce cardiovascular risks, that has not been the case for all options, leading to confusion.

The Medtronic MiniMed 670G system was expanded for pediatric T1D patients, then reported positive real-world symptom management during ADA 2018.

Though the rate of suicidal ideation in pediatric patients with T1D is not significant from general population, girls reported twice as frequent rates.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

The chief medical officer of the Joslin Diabetes Center spoke about how providers communicate with their patients can affect their adherence to medications.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The Healthy MOMs program resulted in positive improvements in diet and depressive symptoms for expecting Latinas, a population at a high risk for gestational and type 2 diabetes.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

The expanded indication provides an important treatment option for clinicians and patients with type 1 diabetes.

The system’s algorithm predicts glucose levels 30 minutes in advance and adjusts insulin delivery to reduce hypoglycemic events.

The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.

The results suggest that this approach could streamline the diagnosis of diabetes, losing the need for the same elevated test needing to be repeated in a new blood sample.

The first patient is anticipated to be enrolled in the third quarter of 2018, and topline results will be expected by the beginning of 2020.

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

Three new studies in diabetes include vitamin D deficiency; eliminating racial disparities in diabetes care; and the link between emotions and insulin resistance. 

The software is now indicated to assist physicians treating patients with T1D who use insulin pumps and continuous glucose monitoring.